Neurocrine Biosciences Inc vs Yum China Holdings Inc — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Yum China Holdings Inc trades at $43.91 (market cap $15.09B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Yum China Holdings Inc pays a 2.64% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | YUMC | |
|---|---|---|
Market Cap | $17.40B | $15.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $57.95 |
52-Week Low | $123.10 | $40.18 |
Enterprise Value | $16.49B | $15.98B |
Dividend Yield | — | 2.64% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →